Faster T-cell development following gene therapy compared with haploidentical HSCT in the treatment of SCID-X1

Blood

Volumn 125, Issue 23, 2015, Pages 3563-3569

  Touzot, Fabien ^a,b,c   Moshous, Despina ^a,b,c   Creidy, Rita ^d   Neven, Bénédicte ^a,b,c   Frange, Pierre ^a,b   Cros, Guilhem ^b,c   Caccavelli, Laure ^a   Blondeau, Johanna ^a   Magnani, Alessandra ^a,b,c   Luby, Jean Marc ^a   Ternaux, Brigitte ^a   Picard, Capucine ^a,b,e   Blanche, Stéphane ^a,b   Fischer, Alain ^a,b,c,f   Hacein Bey Abina, Salima ^a,e,g   Cavazzana, Marina ^a,b,c  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSERM   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^e FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^f Centre de Recherche Interdisciplinaire en Biologie   (France)

^g BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN; RITUXIMAB; THYMOCYTE ANTIBODY; IL2RG PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR GAMMA;

ARTICLE; CELL MATURATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; EPSTEIN BARR VIRUS INFECTION; FEMALE; FRANCE; GENE THERAPY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HAPLOIDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INFANT; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MALE; PATIENT SAFETY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; T CELL DEPLETION; T LYMPHOCYTE; THYMUS; TREATMENT OUTCOME; X LINKED SEVERE COMBINED IMMUNODEFICIENCY; ADOLESCENT; ALLOGRAFT; CLINICAL TRIAL; COMPARATIVE STUDY; GENETICS; GRAFT VS HOST DISEASE; IMMUNOLOGY; MULTICENTER STUDY; MUTATION; PATHOLOGY; PRESCHOOL CHILD; PROSPECTIVE STUDY; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

ADOLESCENT; ALLOGRAFTS; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC THERAPY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT; MALE; MUTATION; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; T-LYMPHOCYTES; THYMUS GLAND; X-LINKED COMBINED IMMUNODEFICIENCY DISEASES;

EID: 84930622918     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-616003     Document Type: Article

References (28)

1. Gennery AR, Slatter MA, Grandin L, et al. Transplantation of hematopoietic stem cells and long-term survival for primary immunodeficiencies in Europe: entering a new century, do we do better? J Allergy Clin Immunol. 2010;126(3):602-610.
2. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009;9(7):480-490.
3. Gaspar HB, Qasim W, Davies EG, Rao K, Amrolia PJ, Veys P. How I treat severe combined immunodeficiency. Blood. 2013;122(23):3749-3758.
4. Pai S-Y, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371(5):434-446.
5. Hacein-Bey-Abina S, Hauer J, Lim A, et al. Efficacy of gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2010;363(4):355-364.
6. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288(5466):669-672.
7. Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142.
8. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415-419.
9. Fischer A, Abina SH-B, Thrasher A, von Kalle C, Cavazzana-Calvo M. LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med. 2004;350(24):2526-2527, author reply 2526-2527.
10. Howe SJ, Mansour MR, Schwarzwaelder K, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest. 2008;118(9):3143-3150.
11. Hacein-Bey-Abina S, Pai S-Y, Gaspar HB, et al. A modified γ-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014;371(15):1407-1417.
12. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364(9452):2181-2187.
13. Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346(16):1185-1193.
14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
15. Le Deist F, Hivroz C, Partiseti M, et al. A primary T-cell immunodeficiency associated with defective transmembrane calcium influx. Blood. 1995;85(4):1053-1062.
16. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 1999;340(7):508-516.
17. Patel NC, Chinen J, Rosenblatt HM, et al. Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol. 2009;124(5):1062-1069.
18. Sarzotti-Kelsoe M, Win CM, Parrott RE, et al. Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras. Blood. 2009;114(7):1445-1453.
19. Borghans JA, Bredius RG, Hazenberg MD, et al. Early determinants of long-term T-cell reconstitution after hematopoietic stem cell transplantation for severe combined immunodeficiency. Blood. 2006;108(2):763-769.
20. Haddad E, Landais P, Friedrich W, et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell-depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91(10):3646-3653.
21. Clave E, Busson M, Douay C, et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood. 2009;113(25):6477-6484.
22. Buckley RH, Win CM, Moser BK, Parrott RE, Sajaroff E, Sarzotti-Kelsoe M. Post-transplantation B cell function in different molecular types of SCID. J Clin Immunol. 2013;33(1):96-110.
23. Avery DT, Deenick EK, Ma CS, et al. B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med. 2010;207(1):155-171.
24. Kotlarz D, Ziętara N, Uzel G, et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med. 2013;210(3):433-443.
25. Brière F, Servet-Delprat C, Bridon JM, Saint-Remy JM, Banchereau J. Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3. J Exp Med. 1994;179(2):757-762.
26. Buckley RH. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. J Allergy Clin Immunol. 2010;125(4):790-797.
27. Haddad E, Leroy S, Buckley RH. B-cell reconstitution for SCID: should a conditioning regimen be used in SCID treatment? J Allergy Clin Immunol. 2013;131(4):994-1000.
28. Patel NC, Chinen J, Rosenblatt HM, et al. Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J. Allergy Clin. Immunol. 2009;124(5):1062-1069.